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I
n this issue of Diabetes, Secrest et al. (1) explore the
long-term cause-speciﬁc mortality experience of
youth diagnosed with type 1 diabetes (18 years of
age over the 15-year period from 1965 to 1979) to
determine if improvements in mortality have occurred
over time. The ﬁndings are at the same time both hopeful
and concerning. The results among these youth (now
middle-aged adults) come from the Alleghany County Type
1 Diabetes Registry established in the mid-1970s. One of
the ﬁrst U.S. registries of type 1 diabetic subjects, it was
one of the archetypical registries that forged the interna-
tional collaboration linking registries in the U.S., Europe,
and Asia (2). The report by Secrest et al. focuses on over 30
years of follow-up among 1,043 subjects with diabetes from
the original 1,075 identiﬁed in the county. This represents
97% known vital status of the original cohort, which ascer-
tained over 95% of the diagnosed cases. This is an amazing
result in this era of rapid residential mobility and increasing
nonresponse to research since vital status was determined by
individual contact of cohort members and next-of-kin. Cause
of death was classiﬁed using internationally standardized
deﬁnitions (3) and all available clinical, hospital, and autopsy
information for 80% of the deaths. Death certiﬁcates were
obtained for all deaths but were only relied upon for 20% of
classiﬁcations, and these underwent adjudication. This is
important since variability of death certiﬁcate coding and
ordering of cause of death can make temporal or geographic
comparisons problematic (4).
What then did the investigators report that I ﬁnd hope-
ful? First, among this largely Caucasian cohort (93%; 7%
African American), total mortality over 30 years of diabe-
tes duration has declined from 800/100,000 person-years in
the earliest cohort (1965–1969) to 530/100,000 person-
years (1975–1979), a 34% reduction in 15 years. Second,
mortality rates for acute complications (largely diabetic
ketoacidosis and hypoglycemia) declined by 57%, along
with reductions in renal disease mortality (38%). Some-
what smaller reductions in cardiovascular disease (CVD)
mortality were also observed (30%). These results are very
hopeful in showing important improvements in mortality
for individuals with type 1 diabetes.
However, among females, there were 30% higher rates
from all diabetes-related causes (overall rate ratio  1.3,
P  0.05) than among males. Total mortality among the
smaller number of African Americans was also more than
doubled compared with Caucasians (relative risk [RR] 
2.5, P  0.001), especially from acute (RR  4.8), renal
(RR  4.6), CVD (RR  1.9), and infectious causes (RR 
2.8). I ﬁnd the results for women and for African Ameri-
cans concerning, especially for the excess of potentially
preventable outcomes such as acute complications. As the
investigators note, this could be the result of socioeco-
nomic disadvantages and poorer access to care, though
this seems less likely for women of Caucasian origin who
still experience excess mortality compared with men.
Increased attention to such disparities is needed and is not
limited to individuals of minority race/ethnicity. Since
women usually have lower rates of mortality than men at
these ages, clinicians must be acutely aware of this
differential and be aggressive in diabetes management.
The other concerning results come from the compar-
isons of cohort mortality to the referent county popula-
tion. Overall, cohort members were 13 times more likely
than their nondiabetic counterparts to die of CVD-
related causes, 104 times more likely for renal disease,
and 41 times more likely for infections. Many studies of
CVD incidence and mortality in adults have suggested only
a two- to threefold excess among older adults (5). What
are the explanations for the very large excesses seen here?
It is likely that some of it is due to the relatively young age
of the cohort (mean age of 40–45 years) with the oldest
members only now reaching their early sixties. These are
decades where CVD mortality in subjects without diabetes
was relatively low, which would exaggerate the excesses
seen. It may also come from the fact that most studies of
CVD mortality are conducted in subjects with type 2 (or
unspeciﬁed) diabetes, and it is possible that the risk is
much greater among subjects with longstanding type 1
diabetes and with a much earlier onset of CVD.
Perhaps the most troubling observation is that there
have been few improvements in cause-speciﬁc mortality in
the more recently diagnosed cohorts when compared with
county residents. For example, CVD mortality was ele-
vated 13.9-fold for the 1965–1969 cohort, and 14.7-fold for
the 1975–1979 cohort. How does one reconcile declining
absolute rates across these cohorts (noted above) with
static or rising standardized mortality ratios (SMRs) com-
pared with the general population? An SMR estimates the
number of deaths expected in a study cohort based on the
mortality rates of the reference population of the same
age, sex, race, and time period. Since total and CVD
mortality have been declining in the nondiabetic popula-
tion at rates often faster than among individuals with
diabetes (6,7), such declines in the county population rates
could actually cause the SMR to rise over time, or, as
observed here, to stay relatively the same. This suggests
that improvements in CVD mortality among nondiabetic
subjects have outpaced the improvements for those with
type 1 diabetes in an era where increased clinical and
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with diabetes has been a major goal.
This cohort developed diabetes during the 1960s and
1970s, well before aggressive treatment of hyperglycemia
and hypertension became the cornerstones of treatment
(8). This may partially explain the excesses in CVD and
renal disease seen in the cohort, given the apparently long
metabolic memory such glycemia entails (9). As Secrest et
al. note, this cohort does not provide a contemporary
picture of mortality early in the course of diabetes, but
provides a much needed description of mortality in cur-
rently middle-aged persons with type 1 diabetes, which
leaves much to be desired. A contemporary exploration of
early mortality among youth newly diagnosed in 2002 and
later is being conducted by the SEARCH for Diabetes in
Youth study group (10).
The Secrest report also does not provide a picture of
how these risk factors were managed. Many of these
factors have been explored by the Pittsburgh group among
a subset of this cohort participating in the Epidemiology of
Diabetes Complications (EDC) study (11) and in compar-
ison with the Diabetes Control and Complications
Trial/Epidemiology of Diabetes Interventions and Compli-
cations (DCCT/EDIC) trial (12). The EDC study, together
with this study of the entire Alleghany County type 1
cohort, provide a unique population-anchored picture that
can serve as a reference standard for the developing
comparative effectiveness research that comes from non-
population-based clinical sources. Such a registry and
cohort studies are valuable national assets in our under-
standing of the continued impact of type 1 diabetes in the
U.S. They should be extended and expanded.
These ﬁndings also show us that there is much yet to
learn about the most effective ways to translate evidence-
based strategies from clinical trials into real-world prac-
tice on a national scale so that the excess mortality
observed in Alleghany County can be further reduced.
Targeted strategies aimed at reducing renal and CVD
mortality among individuals with type 1 diabetes—espe-
cially women and minorities—must be improved. Hope
and concern often coexist.
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